Clinical Trials | September 11, 2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS patients experience neuroinflammation and rapid neurodegeneration
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Subscribe To Our Newsletter & Stay Updated
